Relation of frequency and severity of mitral regurgitation to survival among patients with left ventricular systolic dysfunction and heart failure.

By B. Trichon, G. Felker, L. Shaw, C. Cabell, C. O’Connor. American Journal of Cardiology, 2003

676 citations recorded by the source corpus.

Subfields: Cardiology and Cardiovascular Medicine

View Paper: https://www.semanticscholar.org/paper/764cc14b9e3ce22c088f7fcdca92e17ef6c99ebd

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cardiology and Cardiovascular Medicine

Citations in the corpus

Recommendations for Noninvasive Evaluation of Native Valvular Regurgitation: A Report from the American Society of Echocardiography Developed in Collaboration with the Society for Cardiovascular Magnetic Resonance. (2017, background): “If association with adverse prognosis warrants labeling a lesion as severe, then any degree of secondary MR should be considered clinically significant, since there is evidence that even mild MR is associated with adverse prognosis.(167,168) It is not clear whether the prognostic value of EROA $ 0.”
Guidelines on the management of valvular heart disease (version 2012): the Joint Task Force on the Management of Valvular Heart Disease of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). (2012, neutral): “Several methods can be used to determine the severity of MR. Planimetry of the regurgitant jet should be abandoned, as this measurement is poorly reproducible and depends on numerous factors.”
Guidelines on the management of valvular heart disease The Task Force on the Management of Valvular Heart Disease of the European Society of Cardiology (2006, background): “In patients with secondary MR due to non-ischaemic aetiology, the data regarding the natural history are more limited than in ischaemic MR [145].”
2017 AHA/ACC Focused Update of the 2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. (2017, background): “IIa B-R It is reasonable to choose chordal-sparing MVR over downsized annuloplasty repair if operation is considered for severely symptomatic patients (NYHA class III to IV) with chronic severe ischemic MR (stage D) and persistent symptoms despite GDMT for HF (69,70,125,127,130-139).”
2017 AHA/ACC Focused Update of the 2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. (2017, background): “IIa B-R It is reasonable to choose chordal-sparing MVR over downsized annuloplasty repair if operation is considered for severely symptomatic patients (NYHA class III to IV) with chronic severe ischemic MR (stage D) and persistent symptoms despite GDMT for HF (69,70,125,127,130-139).”